Online inquiry

IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3800MR)

This product GTTS-WQ3800MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets Factor VIIa substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000131.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2155
UniProt ID P08709
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3800MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14994MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ12673MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ286MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ10624MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ13384MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ4519MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ958MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ781MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW